Theravance Biopharma TBPH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Yupelri Monotherapy | $21.85M-11.5% | $24.7M-1.1% | $24.98M+7.6% | $23.22M+13.7% | $20.42M-12.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Theravance Biopharma break its business down?
- Theravance Biopharma (TBPH) reports revenue by product across 2 parts — Licensing And Milestone and Yupelri Monotherapy. Each is extracted from the segment footnotes and tracked over time.
- Where does Theravance Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Theravance Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
